CA2867891C - App specific bace inhibitors (asbis) and uses thereof - Google Patents
App specific bace inhibitors (asbis) and uses thereof Download PDFInfo
- Publication number
- CA2867891C CA2867891C CA2867891A CA2867891A CA2867891C CA 2867891 C CA2867891 C CA 2867891C CA 2867891 A CA2867891 A CA 2867891A CA 2867891 A CA2867891 A CA 2867891A CA 2867891 C CA2867891 C CA 2867891C
- Authority
- CA
- Canada
- Prior art keywords
- alzheimer
- administration
- use according
- subject
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612848P | 2012-03-19 | 2012-03-19 | |
| US61/612,848 | 2012-03-19 | ||
| US201261728688P | 2012-11-20 | 2012-11-20 | |
| US61/728,688 | 2012-11-20 | ||
| PCT/US2013/032481 WO2013142370A1 (en) | 2012-03-19 | 2013-03-15 | APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2867891A1 CA2867891A1 (en) | 2013-09-26 |
| CA2867891C true CA2867891C (en) | 2021-09-14 |
Family
ID=49223272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2867891A Active CA2867891C (en) | 2012-03-19 | 2013-03-15 | App specific bace inhibitors (asbis) and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | USRE49873E1 (enExample) |
| EP (2) | EP2827711B1 (enExample) |
| JP (2) | JP6482458B2 (enExample) |
| KR (2) | KR102160388B1 (enExample) |
| CN (2) | CN104270945B (enExample) |
| AU (2) | AU2013235422B2 (enExample) |
| CA (1) | CA2867891C (enExample) |
| DK (1) | DK2827711T3 (enExample) |
| ES (1) | ES2745539T3 (enExample) |
| WO (1) | WO2013142370A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104270945B (zh) | 2012-03-19 | 2017-03-29 | 巴克老龄化研究所 | App特异性bace抑制剂(asbi)及其用途 |
| US10729777B2 (en) | 2012-04-09 | 2020-08-04 | Case Western Reserve University | Compositions and methods for inhibiting the activity of LAR family phosphatases |
| CN104800200B (zh) * | 2014-01-23 | 2019-04-02 | 上海中医药大学 | 高良姜素的医药用途 |
| JP6797408B2 (ja) | 2014-11-06 | 2020-12-09 | 国立大学法人 長崎大学 | 新規アルツハイマー病治療薬 |
| CA2976258C (en) | 2015-02-18 | 2024-02-20 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| CN106474101A (zh) * | 2015-06-17 | 2017-03-08 | 海南医学院 | 高良姜素在治疗糖尿病脑病药物中的应用 |
| KR101716571B1 (ko) * | 2015-06-19 | 2017-03-15 | 단국대학교 천안캠퍼스 산학협력단 | 알츠하이머성 치매 예방 또는 치료용 약제학적 조성물 |
| WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
| EP3529237A1 (en) | 2016-10-18 | 2019-08-28 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis |
| AU2018281330A1 (en) * | 2017-06-05 | 2019-12-19 | Case Western Reserve University | Compositions and methods for treating alzheimer's disease |
| GB2574878A (en) * | 2018-06-22 | 2019-12-25 | Biofilm Ltd | Oral compositions and mucoadhesive thin films formed therefrom |
| CA3111512A1 (en) | 2018-09-05 | 2020-03-12 | Case Western Reserve University | Methods and compositions for inducing neural plasticity |
| AU2020395610A1 (en) * | 2019-12-06 | 2022-06-30 | Gretals Australia Pty Ltd | Neurologically active flavonoid compositions and methods of use thereof |
| CN111518793A (zh) * | 2020-05-20 | 2020-08-11 | 谭骏 | 年轻人血源APPα-分泌酶在阿尔茨海默病中的应用 |
| US20230302009A1 (en) * | 2020-08-12 | 2023-09-28 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| CN112730839B (zh) * | 2021-01-20 | 2024-01-30 | 宁波海尔施智造有限公司 | 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| CH677886A5 (enExample) | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
| ES2217250T3 (es) | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
| ES2236682T5 (es) | 1991-01-21 | 2011-03-31 | Elan Pharmaceuticals, Inc. | Ensayo y modelo para la enfermedad de alzheimer. |
| AU671093B2 (en) | 1992-01-07 | 1996-08-15 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| FR2730932B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| FR2742676B1 (fr) | 1995-12-21 | 1998-02-06 | Oreal | Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie |
| CA2244774C (en) * | 1996-01-29 | 2006-10-17 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Dihydropyridine derivatives, their preparation and their use as adenosine receptor antagonists |
| FR2755854B1 (fr) | 1996-11-15 | 1998-12-24 | Oreal | Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations |
| FR2760970B1 (fr) | 1997-03-18 | 2000-03-10 | Oreal | Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations |
| US6492377B1 (en) * | 1998-06-25 | 2002-12-10 | Boehringer Ingelheim Pharma Kg | Imidazotriazolopyrimidines with adenosine-antagonistic activity |
| WO2000003819A1 (en) | 1998-07-17 | 2000-01-27 | The Penn State Research Foundation | Full form roll finishing technique |
| PL205294B1 (pl) | 1998-09-24 | 2010-03-31 | Upjohn Co | Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta |
| FR2787027B1 (fr) | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787026B1 (fr) | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787325B1 (fr) | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787326B1 (fr) | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787728B1 (fr) | 1998-12-23 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2787703B1 (fr) | 1998-12-29 | 2001-01-26 | Oreal | Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2788007B1 (fr) | 1999-01-05 | 2001-02-09 | Oreal | Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2788449B1 (fr) | 1999-01-14 | 2001-02-16 | Oreal | Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2789076B1 (fr) | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| US7161962B1 (en) | 1999-05-27 | 2007-01-09 | Nuera Communications, Inc. | Method and apparatus for coding modem signals for transmission over voice networks |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US20010047032A1 (en) | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| FR2811564B1 (fr) | 2000-07-13 | 2002-12-27 | Oreal | Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| AU2002241823A1 (en) | 2001-01-11 | 2002-07-24 | Eastman Chemical Company | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials |
| FR2819427B1 (fr) | 2001-01-18 | 2003-04-11 | Oreal | Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| JP2006512401A (ja) | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
| UY26816A1 (es) * | 2001-07-04 | 2003-04-30 | Horacio Heinzen | Una preparación liposomal de achyrocline satureioides ("marcela"), flavonoides y derivados semisintéticos, para la protección del tejido cerebral frente al dano isquémico- vascular y neurodegenerativo. |
| BRPI0309689B1 (pt) | 2002-04-30 | 2021-06-29 | Unigen, Inc | Composições compreendendo uma mistura de flavonóides de anel-b-livre e flavanos e usos das mesmas |
| US7476393B2 (en) | 2002-11-29 | 2009-01-13 | L'oreal | Process for the preparation of a cationic nanoemulsion, and cosmetic composition |
| WO2005016876A2 (en) | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| AR045219A1 (es) | 2003-08-08 | 2005-10-19 | Pharmacopeia Inc | Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico |
| JP2005104850A (ja) | 2003-09-26 | 2005-04-21 | Kanazawa Univ Tlo Inc | アルツハイマー病の治療薬および予防薬 |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| EP2335701B1 (en) | 2003-12-15 | 2012-07-11 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7468402B2 (en) | 2004-03-17 | 2008-12-23 | Baker Hughes Incorporated | Polymeric nanoemulsion as drag reducer for multiphase flow |
| RU2006144075A (ru) | 2004-06-16 | 2008-07-27 | Вайет (Us) | ДИФЕНИЛИМИДАЗОПИРИМИДИН И -ИМИДАЗОЛАМИНЫ КАК ИНГИБИТОРЫ β-СЕКРЕТАЗЫ |
| BRPI0512213A (pt) | 2004-06-16 | 2008-02-19 | Wyeth Corp | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto |
| KR100610562B1 (ko) * | 2004-06-28 | 2006-08-08 | 재단법인서울대학교산학협력재단 | 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물 |
| CA2574218A1 (en) | 2004-07-22 | 2006-02-09 | Schering Corporation | Substituted amide beta secretase inhibitors |
| CA2575340A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
| CN100441200C (zh) * | 2004-11-26 | 2008-12-10 | 谢德隆 | 石杉碱甲、乙复合成分的蛇足石杉提取物及其制备方法 |
| AR053902A1 (es) | 2005-06-14 | 2007-05-23 | Schering Corp | Inhibidores de aspartil proteasa heterociclicos macrociclicos |
| EP1896406A2 (en) | 2005-06-14 | 2008-03-12 | Shering Corporation | The preparation and use of compounds as protease inhibitors |
| KR20080025079A (ko) | 2005-06-14 | 2008-03-19 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
| WO2006138265A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| PE20070135A1 (es) | 2005-06-14 | 2007-03-09 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas |
| AU2006259675A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| ATE489370T1 (de) | 2005-06-14 | 2010-12-15 | Schering Corp | Herstellung und verwendung von verbindungen als aspartylproteasehemmer |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| AU2006266167A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
| TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| JP2009509957A (ja) | 2005-09-26 | 2009-03-12 | ワイス | β−セクレターゼ阻害剤としてのアミノ−５−［４−（ジフルオロメトキシ）フェニル］−５−フェニルイミダゾロン化合物 |
| ATE478070T1 (de) | 2005-10-27 | 2010-09-15 | Schering Corp | Heterozyklische aspartyl-proteasehemmer |
| JP2009513670A (ja) | 2005-10-31 | 2009-04-02 | シェーリング コーポレイション | アスパルチルプロテアーゼインヒビター |
| CN101460480A (zh) | 2006-04-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 |
| PE20080155A1 (es) | 2006-06-12 | 2008-03-10 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil-proteasa |
| TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
| TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| WO2008011538A2 (en) * | 2006-07-19 | 2008-01-24 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
| US20100016341A1 (en) | 2006-12-12 | 2010-01-21 | Zhaoning Zhu | Aspartyl protease inhibitors containing a tricyclic ring system |
| JP2010512389A (ja) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
| US20090041201A1 (en) | 2007-08-06 | 2009-02-12 | Carestream Health, Inc. | Alignment apparatus for imaging system |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| BRPI0823254A2 (pt) | 2008-11-11 | 2015-06-23 | Inst Materia Medica Cams | Complexos de inclusão de pinocembrina com ciclodextrina ou seus derivados |
| US8466195B2 (en) * | 2009-03-13 | 2013-06-18 | Salk Institute For Biological Studies | Methods and compositions for treating complications of diabetes and vascular diseases using flavones |
| CN101543505A (zh) | 2009-04-29 | 2009-09-30 | 香港科技大学 | 一种预防和治疗阿尔茨海默氏症的药物及其制备方法 |
| US9283204B2 (en) | 2010-08-10 | 2016-03-15 | The Hong Kong University Of Science And Technology | Composition for treating neurodegenerative disease or neuropathological condition |
| CN104270945B (zh) | 2012-03-19 | 2017-03-29 | 巴克老龄化研究所 | App特异性bace抑制剂(asbi)及其用途 |
-
2013
- 2013-03-15 CN CN201380023606.0A patent/CN104270945B/zh active Active
- 2013-03-15 EP EP13763620.5A patent/EP2827711B1/en active Active
- 2013-03-15 JP JP2015501819A patent/JP6482458B2/ja active Active
- 2013-03-15 CA CA2867891A patent/CA2867891C/en active Active
- 2013-03-15 WO PCT/US2013/032481 patent/WO2013142370A1/en not_active Ceased
- 2013-03-15 DK DK13763620.5T patent/DK2827711T3/da active
- 2013-03-15 KR KR1020207002843A patent/KR102160388B1/ko active Active
- 2013-03-15 US US17/382,969 patent/USRE49873E1/en active Active
- 2013-03-15 CN CN201710107804.5A patent/CN106902108B/zh active Active
- 2013-03-15 ES ES13763620T patent/ES2745539T3/es active Active
- 2013-03-15 KR KR1020147029321A patent/KR102073578B1/ko active Active
- 2013-03-15 US US14/384,641 patent/US10357508B2/en not_active Ceased
- 2013-03-15 EP EP19180690.0A patent/EP3607946B1/en active Active
- 2013-03-15 AU AU2013235422A patent/AU2013235422B2/en active Active
-
2017
- 2017-03-08 AU AU2017201599A patent/AU2017201599B2/en active Active
- 2017-12-05 JP JP2017233222A patent/JP2018035197A/ja active Pending
-
2019
- 2019-06-06 US US16/433,879 patent/US10835546B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10357508B2 (en) | 2019-07-23 |
| CN104270945A (zh) | 2015-01-07 |
| JP2018035197A (ja) | 2018-03-08 |
| CN106902108B (zh) | 2020-07-21 |
| KR20200013807A (ko) | 2020-02-07 |
| WO2013142370A1 (en) | 2013-09-26 |
| KR20150002681A (ko) | 2015-01-07 |
| KR102073578B1 (ko) | 2020-02-05 |
| EP2827711A4 (en) | 2016-03-23 |
| AU2017201599B2 (en) | 2018-11-08 |
| CA2867891A1 (en) | 2013-09-26 |
| AU2013235422B2 (en) | 2016-12-15 |
| JP6482458B2 (ja) | 2019-03-13 |
| US20190298748A1 (en) | 2019-10-03 |
| CN106902108A (zh) | 2017-06-30 |
| EP2827711A1 (en) | 2015-01-28 |
| EP3607946B1 (en) | 2023-02-22 |
| KR102160388B1 (ko) | 2020-09-28 |
| DK2827711T3 (da) | 2019-09-23 |
| CN104270945B (zh) | 2017-03-29 |
| JP2015510941A (ja) | 2015-04-13 |
| USRE49873E1 (en) | 2024-03-19 |
| US10835546B2 (en) | 2020-11-17 |
| EP3607946A1 (en) | 2020-02-12 |
| US20150306122A1 (en) | 2015-10-29 |
| EP2827711B1 (en) | 2019-06-19 |
| AU2013235422A1 (en) | 2014-10-02 |
| AU2017201599A1 (en) | 2017-03-30 |
| ES2745539T3 (es) | 2020-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10835546B2 (en) | App specific BACE inhibitors (ASBIs) and uses thereof | |
| US11091444B2 (en) | Hydantoins that modulate BACE-mediated app processing | |
| EP2814491A1 (en) | Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions | |
| US20220041553A1 (en) | Apoe4-targeted theraputics that increase sirt1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180315 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260302 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260302 |